A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants

The main purpose of this study is to measure how much olomorasib gets into the bloodstream and how long it takes the body to get rid of it. Healthy participants will take olomorasib by mouth. The study will last about 7 weeks and will include 10 back-to-back overnight stays in the research center.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

ICON Early Phase Services, San Antonio, Texas, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease
Body mass index (BMI): 18.0 to 30.0 kilograms per square meter (kg/m²), inclusive
Participants assigned male at birth (AMAB) or assigned female at birth (AFAB) who are individuals not of childbearing potential (INOCBP).

Exclusion criteria

Females who are lactating or of childbearing potential
Clinically significant history of any drug sensitivity, drug allergy, or food allergy
Have used or plan to use medication within 14 days or 5 half-lives, whichever is longest, prior to admission, with the exception occasional acetaminophen at doses less than or equal to 2 g/day.

Treatment and study plan

Olomorasib

Drug

Single dose

Other names: LY3537982

Primary outcomes

Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Time Zero to Time t (AUC[0-tlast]) of Olomorasib

Time frame: From Day 1, Predose up to 72 hours Postdose

PK: AUC(0-tlast) of Olomorasib
PK: Area Under the Concentration versus Time Curve from Zero to Infinity (AUC[0-∞]) of Olomorasib

Time frame: From Day 1, Predose up to 72 hours Postdose

PK: AUC(0-∞) of Olomorasib
PK: Maximum Observed Drug Concentration (Cmax) of Olomorasib

Time frame: From Day 1, Predose up to 72 hours Postdose

PK: Cmax of Olomorasib

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

An Open-Label, Randomized, 3-Way Crossover Study Comparing the Pharmacokinetics of Multiple Olomorasib (LY3537982) Capsules

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Jun 29, 2025
Registry last updated: May 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed